P. Clavère

1.8k total citations · 1 hit paper
45 papers, 1.2k citations indexed

About

P. Clavère is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, P. Clavère has authored 45 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in P. Clavère's work include Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (9 papers) and Colorectal Cancer Surgical Treatments (6 papers). P. Clavère is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (9 papers) and Colorectal Cancer Surgical Treatments (6 papers). P. Clavère collaborates with scholars based in France, Serbia and Spain. P. Clavère's co-authors include P. Maingon, M. Bolla, Laurence Collette, Suzana Stojanović-Rundić, Alexander Beny, Jean-François Bosset, Jean-Claude Ollier, É. Bardet, Laurent Mineur and J. Giralt and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

P. Clavère

39 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study

2014 505 citations Jean-François Bosset, G. Calais et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by P. Clavère

Since Specialization

Citations

This map shows the geographic impact of P. Clavère's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Clavère with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Clavère more than expected).

Fields of papers citing papers by P. Clavère

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Clavère. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Clavère. The network helps show where P. Clavère may publish in the future.

Co-authorship network of co-authors of P. Clavère

This figure shows the co-authorship network connecting the top 25 collaborators of P. Clavère. A scholar is included among the top collaborators of P. Clavère based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Clavère. P. Clavère is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42/GERICO 12 study): Quality of life and comprehensive geriatric assessment 2024 ·Radiotherapy and Oncology ·Éric François, Nicolas Magné, Rabia Boulahssass, Philippe Ronchin, (unknown), (unknown), (unknown), C. Cattenoz, Isabelle Martel‐Lafay, C. Terret, Pascal Artru, P. Clavère, Achille Tchalla, V. Vendrely, (unknown), Valérie Boige, (unknown), Jocelyn Gal, Berardino De Bari	0
2	Métier de manipulateur en radiothérapie en tension en France : conséquences organisationnelles et difficultés à déployer de nouvelles missions et/ou délégation de tâches 2023 ·Cancer/Radiothérapie ·C. Bourgier, (unknown), Émilie Bayart, J. Chamois, P. Clavère, (unknown), (unknown), (unknown), Ali Hasbini, (unknown), Patrick Le Tallec, (unknown), (unknown)	1
3	Enquête SFRO–SNRO–AFPPE sur l’évolution du métier de manipulateur exerçant en radiothérapie en France 2023 ·Cancer/Radiothérapie ·(unknown), Émilie Bayart, J. Chamois, P. Clavère, (unknown), (unknown), (unknown), (unknown), Ali Hasbini, Patrick Le Tallec, (unknown), (unknown), (unknown)	1
4	Radiation therapy of cutaneous cancers 2021 ·Cancer/Radiothérapie ·Christophe Hennequin, E. Rio, L. Quéro, P. Clavère	6
5	Facteurs prédictifs de l’ostéoradionécrose mandibulaire après irradiation des cancers des voies aérodigestives supérieures 2021 ·Cancer/Radiothérapie ·(unknown), (unknown), J. Biau, N. Pham Dang, N. Saroul, P. Clavère, M. Lapeyre	7
6	Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group 2020 ·Cancer/Radiothérapie ·Yazid Belkacémi, I. Latorzeff, Ali Hasbini, (unknown), Dominique Pasquier, A. Tolédano, Christophe Hennequin, Alberto Bossi, O. Chapet, G. Créhange, S. Guérif, (unknown), N. Allouache, P. Clavère, (unknown), S. Supiot, D. Azria, M. Bolla, Paul Sargos	2
7	Effets de l’irradiation à haute dose sur la vascularisation : physiopathologie et conséquences cliniques 2019 ·Cancer/Radiothérapie ·(unknown), M. Schlienger, P. Clavère, F. Huguet	11
8	Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study breakdown → 2014 ·The Lancet Oncology ·Jean-François Bosset, G. Calais, Laurent Mineur, P. Maingon, Suzana Stojanović-Rundić, René‐Jean Bensadoun, É. Bardet, Alexander Beny, Jean-Claude Ollier, M. Bolla, (unknown), Jean‐Luc Van Laethem, (unknown), J. Giralt, P. Clavère, Christoph Glanzmann, P. Cellier, Laurence Collette	505
9	Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions 2011 ·Journal of the European Academy of Dermatology and Venereology ·J. J. Bonerandi, Céline Beauvillain, (unknown), (unknown), V. Chaussade, P. Clavère, C. Desouches, Federico Garnier, J.‐L. Grolleau, M Grossin, Anne Jourdain, (unknown), H. Maillard, Nicolás Ortonne, E. Rio, (unknown), J.‐F. Séi, Jean‐Jacques Grob, Ludovic Martin	117
10	Online Quality Control, Hyperfractionated Radiotherapy Alone and Reduced Boost Volume for Standard Risk Medulloblastoma: Long-Term Results of MSFOP 98 2009 ·Journal of Clinical Oncology ·C. Carrié, Jacques Grill, Dominique Figarella‐Branger, V. Bernier, Laëtitia Padovani, Jean Louis Habrand, M. Ben-Hassel, (unknown), M.-A. Mahé, Philippe Quétin, Jean Philippe Maire, Marie Baron, P. Clavère, S. Chapet, P. Maingon, Claire Alapetite, L. Claude, Anne Laprie, Sophie Dussart	49
11	Radiodermatitis prevention with sucralfate in breast cancer: fundamental and clinical studies 2009 ·Supportive Care in Cancer ·(unknown), Patrick Trouillas, Jean‐Luc Duroux, Jean-Marie Bonnetblanc, P. Clavère	18
12	Epirubicin–vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial 2007 ·British Journal of Cancer ·(unknown), Pierre Kerbrat, Henri Roché, Jacques Bonneterre, Corinne Veyret, Alain Lortholary, Alain Monnier, P. Fumoleau, P. Fargeot, M. Namer, P. Chollet, (unknown), B. Audhuy, H. Simon, Philippe Montcuquet, (unknown), Steffen Walter, P. Clavère, J P Guastalla	11
13	Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial 2006 ·Annals of Oncology ·Henri Roché, Pierre Kerbrat, Jacques Bonneterre, P. Fargeot, P. Fumoleau, Alain Monnier, P. Clavère, Marie-Josèphe Goudier, P. Chollet, Jean‐Paul Guastalla, D. Serin	48
14	Inflammatory breast cancer outcome with epirubicin‐based induction and maintenance chemotherapy 2006 ·Cancer ·Corinne Veyret, Christelle Lévy, P. Chollet, Yacine Merrouche, Henri Roché, Pierre Kerbrat, P. Fumoleau, P. Fargeot, P. Clavère, Bernard Chevallier	27
15	[Acute and chronic radiodermatitis]. 2003 ·PubMed ·(unknown), P. Clavère, (unknown)	2
16	[Radiation induced skin reaction]. 2001 ·PubMed ·(unknown), P. Clavère, (unknown)	2
17	A proliferative vascular tumour of the skin in a kidney-transplant recipient (recurrent pyogenic granuloma with satellitosis) 1997 ·Nephrology Dialysis Transplantation ·Yannick Le Meur, C. Bédane, P. Clavère, P. Peyronnet, C. Leroux‐Robert	6
18	Postoperative Interstitial Radiotherapy of Keloids by Iridium 192: A Retrospective Study of 46 Treated Scars 1997 ·Dermatology ·P. Clavère, C. Bédane, Jean-Marie Bonnetblanc, (unknown), Julia Rousseau	34
19	Prospective randomized study of mitoxantrone (M) and vinorelbine (V) vs fluorouracil (F), epirubicin (E) or adriamycin (A) and cyclophosphamide (C) in patients with advanced breast cancer (ABC) 1997 ·European Journal of Cancer ·F Turpin, D. Serin, G. Ganem, G. Calais, P. Maillart, P. Colin, Grégoire Prévost, (unknown), (unknown), P. Clavère, M. Namer	0
20	Valeur prédictive des variations de l'activité sérique de la DNAse alcaline dans le pronostic des cancers des voies aérodigestives supérieures traités par chimiothérapie. 1990 ·Bulletin du Cancer ·Bernard Roullet, M Labadie, Henryk Taper, M. Lans, (unknown), (unknown), Marcel Roberfroid, (unknown), (unknown), P. Clavère	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact